AbirateroneSolubilityInclusion complexHydroxypropyl-β-cyclodextrinAbiraterone acetate (ABA), a precursor drug inhibiting androgen biosynthesis (CYP17 inhibitor), is used for treating metastatic castration-resistant prostate cancers. However, it falls under the Biopharmaceutical Classification System Class IV due...
Abiraterone acetate (Zytiga?) Abiraterone acetate (often shortened to abiraterone) is a hormonal therapy drug used to treat advanced prostate cancer. It is also known as Zytiga?. View all Originator Abiraterone,Cougar Uses Prasteronyl Abiraterone is a dimer impurity of Abiraterone (A108490), a ...
The starting treatment concentration of abiraterone acetate (MedChemExpress, NJ 08852, USA) in the parental C4-2 cell culture medium was 0.5 μM. At this concentration, the cells were stably passaged three times. The drug concentration was then increased, and the culture was continued. The...
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67:795–802. Article CAS Google Scholar Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced ...
Patients with advanced CSPC were randomized (1:1:1) to receive goserelin plus abiraterone acetate and prednisone (ADT plus AAP arm), apalutamide (APA arm), or apalutamide plus abiraterone acetate and prednisone (APA plus AAP arm). The primary endpoint was the proportion of patients with PSA...
DRUG side effectsPROSTATE-specific antigenABIRATERONE acetatePROGRESSION-free survivalPurpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC)...
Keywords castration-resistant prostate cancer sarcopenia abiraterone acetate Subjects Drug therapy Hormonal therapies Prostate cancer This article is cited by Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer Erik D. Hanson Mohamdod Alzer Claudio L. Batt...